Bladder cancer: shedding light on the most promising investigational drugs in clinical trials

References

• Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update. World J Urol. 2020 2020/08/01;38(8):1895–1904.
   PubMed Web of Science ®Google Scholar
• Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018 Dec;74(6):784–795.
   PubMed Web of Science ®Google Scholar
• Kamoun A, De Reyniès A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 20202020/04/01;77(4):420–433.
   PubMed Web of Science ®Google Scholar
• Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005 Dec;66(6 Suppl 1):4–34.
   PubMedGoogle Scholar
• Leal J, Luengo-Fernandez R, Sullivan R, et al. Economic burden of bladder cancer across the European Union. Eur Urol. 2016 Mar;69(3):438–447.
   PubMed Web of Science ®Google Scholar
• Lenis AT, Lec PM, Chamie K, et al. Bladder cancer: a review. JAMA. 2020;324(19):1980–1991.
   PubMed Web of Science ®Google Scholar
• Linton KD, Rosario DJ, Thomas F, et al. Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance. J Urol. 2013 Mar;189(3):828–833.
   PubMed Web of Science ®Google Scholar
• Catto JWF, Gordon K, Collinson M, et al. Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study. J Clin Oncol. 2021 2021/01;39(3):202–214.
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Cimadamore A, Blanca A, et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers (Basel). 2021 Jan 3;13(1):131.
   Web of Science ®Google Scholar
• Balar AV, Kulkarni GS, Uchio EM, et al. Keynote 057: phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG). J clin oncol. 2019;37(7_suppl): 350-350. DOI:10.1200/JCO.2019.37.7_suppl.350.
   PubMed Web of Science ®Google Scholar
• Lerner SP, Bajorin DF, Dinney CP, et al. Summary and recommendations from the National Cancer Institute’s clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer. Bladder Cancer. 2016 Apr 27;2(2):165–202.
   PubMed Web of Science ®Google Scholar
• Gill J, Prasad V. Pembrolizumab for Non–muscle-invasive bladder cancer—a costly therapy in search of evidence. JAMA Oncol. 2020;7:501.
   Web of Science ®Google Scholar
• Wang Y, Liu J, Yang X, et al. Bacillus Calmette-Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer. Onco Targets Ther. 2018;11:2891–2899.
   PubMed Web of Science ®Google Scholar
• Golla V, Lenis AT, Faiena I, et al. Intravesical therapy for non-muscle invasive bladder cancer-current and future options in the age of bacillus Calmette-Guerin shortage. Rev Urol. 2019;21(4):145–153.
   PubMedGoogle Scholar
• Boorjian SA, Alemozaffar M, Konety BR, et al., Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107–117.
   PubMed Web of Science ®Google Scholar
• Kulkarni GS. Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer? Lancet Oncol. 2021;22(1):8–9.
   PubMed Web of Science ®Google Scholar
• Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019 Aug 31;394(10200):793–804.
   PubMed Web of Science ®Google Scholar
• Riaz IB. Antibody-drug conjugates for treatment of urothelial carcinoma ASCO daily news2020; [ cited 2020 Mar 12]. Available from: https://dailynews.ascopubs.org/do/10.1200/ADN.20.200381/full
   Google Scholar
• Kowalski M, Entwistle J, Cizeau J, et al. A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients. Drug Des Devel Ther. 2010 Nov;15(4):313–320.
   Google Scholar
• Dickstein R, editor. vista, phase 3 trial of vicinium, an epcam targeted pseudomonas exotoxin, in bcg unresponsive non muscle invasive bladder cancer. Bladder Congr. 2018:2018.
   Google Scholar
• David Fabrizio, PhD1, Shu-Jen Chen, et al.33rd annual meeting & pre-conference programs of the society for immunotherapy of cancer (SITC 2018): late-Breaking Abstracts: washington, D.C., USA. 7-11 November 2018. J Immunother Cancer. 2018;6(Suppl2):1–13.
   PubMedGoogle Scholar
• QUILT-3.032. A multicenter clinical trial of intravesical Bacillus Calmette-Guerin (BCG) in combination with ALT-803 in patients with BCG unresponsive high grade non-muscle invasive bladder cancer [Internet]; ClinicalTrials.gov; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT03022825?term=ALT-803.
   Google Scholar
• Packiam VT, Lamm DL, Barocas DA, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol. 2018 Oct;36(10):440–447.
   PubMed Web of Science ®Google Scholar
• Pang KH, Thomas F, Novara G, et al. The impact of centralised services on metric reflecting high-quality performance: outcomes from 1110 consecutive radical cystectomies at a single centre. Eur Urol Focus. 2020 Jun 21. DOI:10.1016/j.euf.2020.05.011.
   PubMedGoogle Scholar
• Freshwater T, Li H, Valiathan C, et al. Systematic literature review and meta-analysis of response to first-line therapies for advanced/metastatic urothelial cancer patients who are cisplatin ineligible. Am J Clin Oncol. 2019 Oct;42(10):802–809.
   PubMed Web of Science ®Google Scholar
• Pfister C, Gravis G, Fléchon A, et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol. 2021 Feb;79(2):214–221.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Tangen CM, Daneshmand S, et al. A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 Feb 10;27(9):2435–2441.
   PubMed Web of Science ®Google Scholar
• Gupta S, Sonpavde G, Weight CJ, et al. Results from BLASST-1 (bladder cancer signal seeking trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. J clin oncol. 2020 2020/02/20;38(6_suppl): 439-439. DOI:10.1200/JCO.2020.38.6_suppl.439.
   Web of Science ®Google Scholar
• Hoimes C, editor. A Phase Ib/2 study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced Urothelial Cancer (UC). ESMO 2018 Congress; 2018 08/20/2018.
   Google Scholar
• Hussain SA, Lester JF, Jackson R, et al. Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE). J clin oncol. 2020 2020/02/20;38(6_suppl): 438-438. DOI:10.1200/JCO.2020.38.6_suppl.438.
   Web of Science ®Google Scholar
• Hanna N, Trinh QD, Seisen T, et al. Effectiveness of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the current real world setting in the USA. Eur Urol Oncol. 2018 May;1(1):83–90.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol. 2011 Jun 10;29(17):2432–2438.
   PubMed Web of Science ®Google Scholar
• van Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 20202020/12/01;26(12):1839–1844.
   PubMed Web of Science ®Google Scholar
• Gao J, Navai N, Alhalabi O, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 20202020/12/01;26(12):1845–1851.
   PubMed Web of Science ®Google Scholar
• Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019 Nov;25(11):1706–1714.
   PubMed Web of Science ®Google Scholar
• Necchi A, Raggi D, Gallina A, et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020 Apr;77(4):439–446.
   PubMed Web of Science ®Google Scholar
• Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404–423.
   PubMed Web of Science ®Google Scholar
• Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2015 Dec;68(6):959–967.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014 Oct;4(10):1140–1153.
   PubMed Web of Science ®Google Scholar
• Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012 Sep;12(9):587–598.
   PubMed Web of Science ®Google Scholar
• Booth CM, Tannock IF. Benefits of adjuvant chemotherapy for bladder cancer. JAMA Oncol. 2015;1(6):727–728.
   PubMed Web of Science ®Google Scholar
• Hussain M, editor .ASCO 2020: iMvigor010: primary analysis from a phase III randomized study of adjuvant atezolizumab versus observation in high-risk muscle-invasive urothelial carcinoma. ASCO 2020 Bladder Cancer.
   Google Scholar
• Opdivo Significantly Improves Disease Free-Survival vs. Placebo as adjuvant therapy for patients with high-risk, muscle-invasive urothelial carcinoma in phase 3 CheckMate −274 trial [Internet]; 2020 [cited 2020 Sep 24]. Available from: https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/124764-opdivo-nivolumab-significantly-improves-disease-free-survival-vs-placebo-as-adjuvant-therapy-for-patients-with-high-risk-muscle-invasive-urothelial-carcinoma-in-phase-3-checkmate-274-trial.html
   Google Scholar
• Testing MK-3475 (Pembrolizumab) after surgery for localized muscle-invasive bladder cancer and locally advanced urothelial cancer (AMBASSADOR); 2021 [ cited 2021]. Available from: https://clinicaltrials.gov/ct2/show/NCT03244384
   Google Scholar
• Powles T, Meeks JJ, Galsky MD, et al. A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA). J clin oncol. 2019;37(15_suppl): TPS4592–TPS4592.
   Google Scholar
• Huddart RA, Birtle A, Maynard L, et al. Clinical and patient-reported outcomes of SPARE – a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int. 2017;120(5):639–650.
   PubMed Web of Science ®Google Scholar
• Giacalone NJ, Shipley WU, Clayman RH, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the massachusetts general hospital experience. Eur Urol. 2017 Jun;71(6):952–960.
   PubMed Web of Science ®Google Scholar
• Premo C, Apolo AB, Agarwal PK, et al. Trimodality therapy in bladder cancer: who, what, and when? Urol Clin North Am. 2015 May;42(2):169–80, vii.
   PubMed Web of Science ®Google Scholar
• Caffo O, Thompson C, De Santis M, et al. Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: a pooled individual data analysis of eight phase I-II trials. Radiother Oncol. 2016 Nov;121(2):193–198.
   PubMed Web of Science ®Google Scholar
• Wang Y, Deng W, Li N, et al. Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions. Front Pharmacol. 2018;9:185.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20;27(27):4454–4461.
   PubMed Web of Science ®Google Scholar
• Ko YJ, Canil CM, Mukherjee SD, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol. 2013 Jul;14(8):769–776.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006 Jul 20;24(21):3451–3457.
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76.
   PubMed Web of Science ®Google Scholar
• Vuky J, Balar AV, Castellano D, et al. Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol. 2020 Aug 10;38(23):2658–2666.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Arija JÁA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547–1557.
   PubMed Web of Science ®Google Scholar
• ESMO Virtual Congress. Pembrolizumab combined with chemotherapy vs chemotherapy alone as first-line therapy for advanced urothelial carcinoma: KEYNOTE-361 [Internet]. ESMO virtual congress 2020; 2020; [cited 2020 Sep 21]. Available from: https://www.urotoday.com/conference-highlights/esmo-2020/bladder-cancer/124537-esmo-virtual-congress-2020-pembrolizumab-combined-with-chemotherapy-vs-chemotherapy-alone-as-first-line-therapy-for-advanced-urothelial-carcinoma-keynote-361.html
   Google Scholar
• Update on Phase III DANUBE trial for Imfinzi and tremelimumab in unresectable, Stage IV bladder cancer [Internet]. 2020; [2020 Mar 06]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-danube-trial-for-imfinzi-and-tremelimumab-in-unresectable-stage-iv-bladder-cancer-06032020.html
   Google Scholar
• Powles T, Park SH, Voog E, et al., Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–1230.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Mortazavi A, Milowsky MI, et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. J Clin Oncol. 2020 Jun 1;38(16):1797–1806.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019 Oct 10;37(29):2592–2600.
   PubMed Web of Science ®Google Scholar
• Phase 3 EV-301 trial of enfortumab vedotin-ejfv meets primary end point for urothelial cancer [Internet]; Cancer Network; 2020. EV–301; [2020 Sept 18]. Available from: https://www.cancernetwork.com/view/phase-3-ev-301-trial-of-enfortumab-vedotin-ejfv-meets-primary-end-point-for-urothelial-cancer
   Google Scholar
• ASCO GU 2020: study EV-103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma; ASCO GU 2020; 2020. urotoday.com.
   Google Scholar
• Sharma P, Siefker-Radtke A, Braud F, et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: checkMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion Cohort results. J clin oncol. 2019;37(19):1608–1616.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Kania BE, Iyer G, et al. Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC). J clin oncol. 2017;35(6_suppl): 384-384. DOI:10.1200/JCO.2017.35.6_suppl.384.
   PubMed Web of Science ®Google Scholar
• Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019 Jul 25;381(4):338–348.
   PubMed Web of Science ®Google Scholar
• Pal SK, Rosenberg JE, Hoffman-Censits JH, et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 2018 Jul;8(7):812–821.
   PubMed Web of Science ®Google Scholar
• ESMO Virtual Congress. TROPHY-U-01 Cohort 1 final results: a phase 2 study of Sacituzumab Govitecan (SG) in metastatic urothelial cancer that has progressed after platinum and checkpoint inhibitors. ESMO Virtual Cong. 2020;2020:2020.
   Google Scholar
• Petrylak DP, Tagawa ST, Jain RK, et al., Early results of TROPHY-U-01 Cohort 2: sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy. J clin oncol. 2020;38(15_suppl): 5027-5027. 10.1200/JCO.2020.38.15_suppl.5027.
   Web of Science ®Google Scholar